sumanirole
Sponsors
Pfizer
Conditions
Parkinson Disease
Phase 3
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
CompletedNCT00036218
Start: 2001-12-31End: 2003-04-30Target: 600Updated: 2006-06-07
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's Disease
TerminatedNCT00036205
Start: 2000-08-31End: 2004-12-31Target: 984Updated: 2007-01-18
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease
CompletedNCT00058838
Start: 2003-04-30End: 2004-09-30Target: 854Updated: 2006-06-07